BioRestorative Therapies, Inc. (BRTX)
NASDAQ: BRTX · Real-Time Price · USD
1.970
-0.070 (-3.43%)
Jan 17, 2025, 4:00 PM EST - Market closed
BioRestorative Therapies Employees
BioRestorative Therapies had 11 employees as of December 31, 2023. The number of employees increased by 1 or 10.00% compared to the previous year.
Employees
11
Change (1Y)
1
Growth (1Y)
10.00%
Revenue / Employee
$34,273
Profits / Employee
-$877,021
Market Cap
13.63M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 122,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 89,900 |
Novartis AG | 76,057 |
Merck & Co. | 72,000 |
Novo Nordisk | 64,319 |
BRTX News
- 6 weeks ago - BioRestorative Therapies Announces Notice of Allowance of Key New Patent Protecting ThermoStem® Metabolic Disease Program - GlobeNewsWire
- 2 months ago - BioRestorative Therapies, Inc. (BRTX) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 2 months ago - BioRestorative Therapies Receives Expanded Tissue License from New York State Department of Health - GlobeNewsWire
- 3 months ago - BioRestorative Therapies to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference - GlobeNewsWire
- 4 months ago - BioRestorative Therapies' IFATS 2024 Presentation to Feature ThermoStem® Platform's Potential to Deliver a Superior Efficacy and Tolerability Profile Over GLP-1 Drugs - GlobeNewsWire
- 5 months ago - BioRestorative Therapies, Inc. (BRTX) Q2 2024 Earnings Call Transcript - Seeking Alpha
- 6 months ago - BioRestorative Therapies' Chief Scientist Named New Section Editor of the Prestigious Journal of Translational Medicine - GlobeNewsWire
- 7 months ago - BioRestorative Therapies Announces Notice of Allowance for Patent Covering Fundamental Aspect of ThermoStem® Metabolic Disease Program - GlobeNewsWire